GlassScriptPhysician profile
Albert Klemptner
NPI 1952396129
$3,126.04
in general payments reported to CMS, 2019-2025
24 companies · $553 in 2025
The $553 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $473 · 2021: $618 · 2022: $527 · 2023: $180 · 2024: $300 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,302.22 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $338.61 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Esperion Therapeutics, INC. | $289.55 | 2021 | |
| Novo Nordisk INC | $213.76 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.56 | 2020-2025 | Jardiance |
| Amarin Pharma, INC. | $103.43 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $95.79 | 2019 | |
| Abbvie INC. | $89.84 | 2019-2023 | |
| Pfizer INC. | $68.88 | 2019-2025 | |
| Lilly USA, LLC | $61.99 | 2019-2025 | Zepbound, Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $60.06 | 2022 | |
| Merck Sharp & Dohme LLC | $58.01 | 2020-2021 | |
| Lundbeck LLC | $57.09 | 2023-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $42.98 | 2025 | Eliquis |
| Supernus Pharmaceuticals, INC. | $31.06 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23.53 | 2019 | |
| Corcept Therapeutics | $21.13 | 2019 | |
| Almatica Pharma LLC | $20.94 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.76 | 2021 | |
| Kci USA, INC. | $19.96 | 2021 | |
| Sk Life Science, INC. | $17.97 | 2020 | |
| Circassia INC. | $16.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.02 | 2020 | |
| Allergan, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Klemptner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.